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The recent identification of a high-level-ceftriaxone-resistant (MIC  2 to 4 g/ml) isolate of Neisseria gonorrhoeae from Japan
(H041) portends the loss of ceftriaxone as an effective treatment for gonococcal infections. This is of grave concern because
ceftriaxone is the last remaining option for first-line empirical antimicrobial monotherapy. The penA gene from H041 (penA41)
is a mosaic penA allele similar to mosaic alleles conferring intermediate-level cephalosporin resistance (Cephi) worldwide but
has 13 additional mutations compared to the mosaic penA gene from the previously studied Cephi strain 35/02 (penA35). When
transformed into the wild-type strain FA19, the penA41 allele confers 300- and 570-fold increases in the MICs for ceftriaxone and
cefixime, respectively. In order to understand the mechanisms involved in high-level ceftriaxone resistance and to improve sur-
veillance and epidemiology during the potential emergence of ceftriaxone resistance, we sought to identify the minimum num-
ber of amino acid alterations above those in penA35 that confer high-level resistance to ceftriaxone. Using restriction fragment
exchange and site-directed mutagenesis, we identified three mutations, A311V, T316P, and T483S, that, when incorporated into
the mosaic penA35 allele, confer essentially all of the increased resistance of penA41. A311V and T316P are close to the active-site
nucleophile Ser310 that forms the acyl-enzyme complex, while Thr483 is predicted to interact with the carboxylate of the -lac-
tam antibiotic. These three mutations have thus far been described only for penA41, but dissemination of these mutations in
other mosaic alleles would spell the end of ceftriaxone as an effective treatment for gonococcal infections.
Neisseria gonorrhoeae is the etiologic agent of the sexually trans-mitted infection gonorrhea. The World Health Organization
estimates that there were 106 million gonococcal infections
worldwide in 2008, a 21% increase from the rate in 2005 (1).
Gonococcal infections are often asymptomatic, which contributes
to the continued transmission of the infection, and if left un-
treated, gonorrhea can progress to pelvic inflammatory disease,
ectopic pregnancy, and infertility. In the absence of a vaccine,
effective prevention, diagnosis, and particularly antibiotics are the
mainstays for treatment and control of gonococcal infections.
N. gonorrhoeae has shown a remarkable ability to become re-
sistant to nearly every antibiotic used to treat infections (2, 3).
Penicillin was introduced in 1943 and was effective for nearly 40
years, but during this time, the MICs of the -lactam antimicro-
bials gradually increased (MIC “creep”) until the emergence of
chromosomally mediated resistant strains in the mid-1980s, as
well as of -lactamase-producing strains worldwide (4), necessi-
tated its removal as a recommended antibiotic. During this time,
resistance to spectinomycin, tetracycline, and erythromycin ren-
dered them unsuitable for treatment of gonococcal infections as
well. Fluoroquinolones were introduced in the United States in
1989 as antigonococcal antibiotics, but by 2007, resistance became
so widespread that the Centers for Disease Control and Preven-
tion (CDC) removed these antibiotics from the recommended list
(5), leaving only the expanded-spectrum cephalosporins ceftriax-
one and cefixime. Worryingly, over the most recent decade, the
number of strains with increased resistance to ceftriaxone and
cefixime has steadily increased (6), and in vitro resistance and
treatment failures with cefixime and some with ceftriaxone have
been verified in Japan, Europe, and Canada (3, 7). This has
prompted the recent revision of CDC (8) and European (9) treat-
ment guidelines so that only ceftriaxone together with azithromy-
cin is now recommended for treatment of uncomplicated gonor-
rhea. Nevertheless, the threat of widespread resistance to
ceftriaxone and possibly untreatable gonorrhea is real, especially
in settings where ceftriaxone monotherapy is common and dual
antimicrobial therapy is neither feasible nor affordable, and there
are few potentially useful antibiotic options in the pipeline (3).
Chromosomally mediated resistance to penicillin is conferred
by multiple resistance determinants that are mutated versions of
endogenous genes. These determinants are penA, which encodes
penicillin-binding protein 2 (PBP2), an essential transpeptidase
(TPase) involved in cell division; mtrR, which increases the ex-
pression of the MtrC-MtrD-MtrE efflux pump (10, 11); penB,
encoding mutations in the constriction loop of PorB1b, the major
outer membrane porin (12–14); ponA, encoding a mutated vari-
ant of the other essential PBP in the gonococcus, PBP1 (15); and a
nontransformable resistance determinant involved in high-level
resistance whose genetic identity is unknown (15). Each of these
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determinants increases resistance incrementally (2- to 6-fold), but
together, the determinants increase resistance to penicillin by 400-
fold (15, 16).
The resistance determinants harbored by strains with interme-
diate resistance to cephalosporin (Cephi) are very similar, with the
major difference residing in the penA gene. Whereas most peni-
cillin-resistant strains have a penA gene with 4 to 8 mutations
relative to a wild-type penA gene (17), Cephi strains harbor mosaic
penA genes that contain upwards of 60 to 70 mutations, which
have arisen through DNA recombination with multiple Neisseria
species penA genes (18, 19). The initial Cephi strains emerged in
Japan and then spread to other parts of the world (3, 18–22).
Very recently, a strain (referred to as H041) isolated in Ja-
pan from a female sex worker was found to have very high
MICs of both ceftriaxone (MIC  2 to 4 g/ml) and cefixime
(MIC  8 g/ml) and was resistant to most other antibiotics
(23, 24). This strain contains a novel mosaic penA allele (re-
ferred to as penA41) with 61 amino acid differences compared
to a wild-type allele, with several of these mutations being
unique among the 40 mosaic penA alleles reported thus far.
The penA41 allele confers resistance to both ceftriaxone and
cefixime well above the current breakpoints (0.25 g/ml for
both), even when transferred to a wild-type strain, with MICs
5- to 10-fold higher in strains with additional resistance deter-
minants (i.e., mtrR and penB) (24).
Knowing the identity of the amino acid alterations that directly
result in the high-level cephalosporin resistance conferred by the
mosaic penA41 allele is critical for both understanding the mech-
anisms involved in PBP2 remodeling and monitoring the resis-
tance potential of new strains that appear certain to emerge in the
near future. In this study, we set out to identify the mutations in
penA41 that are responsible for the marked increase in resistance
to the expanded-spectrum cephalosporins relative to a standard
mosaic penA allele. We identified three novel mutations, A311V,
V316P, and T483S, that, when incorporated into the mosaic
penA35 allele, are responsible for essentially all of the additional
resistance conferred by penA41. Two of these mutations, A311V
and T316P, are located near the active-site nucleophile Ser310, in
a region previously shown to harbor mutations that increase re-
sistance (25), whereas the remaining mutation, T483S, is in a dif-
ferent location in the structure of PBP2, where it may interact with
the -lactam carboxylate.
MATERIALS AND METHODS
Bacterial strains and culture conditions. FA19 is a wild-type penicillin-
and cephalosporin-susceptible strain that we have used extensively as a
genetic recipient for antimicrobial resistance determinants (26). FA6140
is a penicillin-resistant, cephalosporin-susceptible strain isolated in Dur-
ham, NC, in 1986 that contains all of the known penicillin resistance
determinants found in clinical isolates (27). Strains were grown on GC
broth (GCB) agar plates containing supplements I and II (28) in a 4%
CO2–96% air atmosphere at 37°C.
Chimeric penA construction and site-directed mutagenesis. To
identify the regions containing amino acid mutations conferring resis-
tance, we utilized a plasmid (pUC18us-penA35-REs) containing the
penA35 gene (mosaic penA allele XXIX) (24, 25) and 300 bp of down-
stream sequence into which silent restriction sites were incorporated
within the coding sequence, splitting the gene into 6 modules (mod0 to
mod5) (25). The corresponding modules from penA41 (mosaic penA al-
lele C [24, 29]) were created by amplifying the modules from penA41 with
primers harboring the appropriate silent restriction sites at their 5= ends
and replacing the corresponding modules in pUC18us-penA35-REs. After
verification of the incorporated sequence, the plasmid was used to trans-
form FA19, as described below.
Individual mutations were incorporated into penA35 by using over-
lap-extension PCR (30) with pUC18us-penA35-REs as a template. The
outside primers spanned the silent restriction sites of the module being
mutagenized, and after the second PCR amplification, the mutagenized
module was digested with the appropriate restriction enzymes and re-
placed by the corresponding fragment from pUC18us-penA35-REs. For
the A311V and T316P mutations, which were very close to the BamHI
restriction site at codon 309, the mutations were introduced into the
BamHI-containing primer, and the amplified fragment was used to re-
place the corresponding fragment in the plasmid. The resulting plasmids
were verified by DNA sequencing and used in transformation experi-
ments, as described below.
Transformation experiments. DNA transformations in N. gonor-
rhoeae were performed essentially as described previously (16). Briefly,
900 l of piliated FA19 at an optical density at 600 nm (OD600) of 0.18 in
GCB with supplements I and II (28), 10 mM MgCl2, and 20 mM bicar-
bonate was added to 2 g of plasmid in 100 l of 1 SSC (1 SSC is 0.15
M NaCl plus 0.015 M sodium citrate), and the cells and DNA were incu-
bated in a 37°C incubator in a 4% CO2–96% air atmosphere for 5 h. At the
end of the incubation, 300 l of the mixture was removed, and the cells
were pelleted, resuspended in 50 l GCB, and plated onto GCB plates
containing 0.05 to 1.0 g/ml cefixime. After overnight incubation, mul-
tiple clones from each transformation were passaged, and frozen stocks
were made.
To test for correct recombination, several colonies from each passaged
clone were resuspended in H2O and boiled for 10 min, and cell debris was
pelleted by centrifugation. The supernatants (2 l) were subsequently
used to amplify the penA gene with Taq polymerase, and PCR products
were purified and sequenced with sense primers that covered the coding
sequence from codon 48 to the end of the gene.
MIC measurements. Two to four verified clones from each individual
transformation were passaged on GCB plates and resuspended at an
OD600 of 0.18. GCB plates containing 2-fold changes in concentrations
of ceftriaxone and cefixime were poured on the day of the experiment, and
agar dilution MICs were determined as previously described (16, 25).
Aliquots (5 l; 50,000 CFU) of each clone were spotted onto the anti-
biotic-containing plates, and the plates were incubated overnight. The
next morning, growth was scored, in which growth was defined as 5
colonies growing in the spot. The MIC determinations were repeated a
minimum of three times, and the values for each mutant were averaged.
Kinetic analysis of PBP2 acylation by -lactam antibiotics. PBP2
mutant proteins were purified and used to determine the k2/Ks values for
their acylation rates with penicillin, ceftriaxone, and cefixime, as de-
scribed previously (25, 31). The reaction of -lactam antibiotics with







where E · S is the noncovalent enzyme-antibiotic complex, E-S= is the acyl-
enzyme complex, and P is the hydrolyzed antibiotic. k2/Ks constants, which
are a direct measure of the ability of an antibiotic to inhibit a PBP (32), were
calculated from first-order rates of acylation of purified, soluble PBP2 vari-
ants by [14C]penicillin G (Moravek, Brea, CA), as previously described
(25, 31, 33). Graphs of PBP2-[14C]penicillin G complex formation
versus time were obtained by incubating 32 g of protein with 25 to
125 M [14C]penicillin G, aliquots of 5 g were removed at 15-s
intervals, precipitated with 5% trichloroacetic acid, and filtered over
Whatman GC-A filters, and the filters were submitted to scintillation
counting. The k2/Ks values of nonradioactive cephalosporin antibiot-
ics were derived by determining the concentration of the cephalospo-
rins that inhibited 50% of the binding of a known amount of
[14C]penicillin G (32). The k2/Ks values were then determined by using
the equation k2⁄KsCeph  k2⁄Ks PenG PenGCeph0.5, where [PenG] is the
concentration of [14C]penicillin G used in the reaction and [Ceph]0.5 is
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the concentration of cephalosporin antibiotic that inhibits the binding of
[14C]penicillin G by 50%.
RESULTS
The mosaic penA allele from H041. The penA gene from the high-
level-cephalosporin-resistant isolate H041 (MICs of 2 to 4 g/ml
and 8 g/ml for ceftriaxone and cefixime, respectively [24]) is a
mosaic allele that encodes a PBP2 variant with 61 amino acid
alterations compared to wild-type PBP2 and 13 alterations com-
pared to PBP2 from the intermediate-level-cephalosporin-resis-
tant strain 35/02 (PBP235/02) (Fig. 1A). Twelve of the 13 mutations
relative to 35/02 are located in the penicillin-binding domain
(amino acids 240 to 581). The penA alleles from 35/02 and H041
were transformed into either a wild-type strain (FA19) or a peni-
cillin-resistant, cephalosporin-susceptible strain containing all of
the known penicillin resistance determinants (FA6140), and the
MICs of ceftriaxone and cefixime were determined (Fig. 2). Com-
pared to FA19, the MICs of ceftriaxone for the FA19 transfor-
mants containing penA35 and penA41 increased 20-fold and 300-
fold, respectively, while the MICs of cefixime for the same
transformants increased 45-fold and 570-fold, respectively. For
FA6140, the MICs of ceftriaxone increased 4.5-fold and 75-fold in
the transformants containing penA35 and penA41, respectively,
while the MICs of cefixime increased 10-fold and 170-fold, respec-
tively (Fig. 2). These data highlight the dramatic increases in re-
sistance to expanded-spectrum cephalosporins conferred by the
penA41 gene.
We then sought to identify which of the amino acids in
FIG 1 Alignment of PBP2 from FA19 (wild-type), 35/02 (Cephi), and H041 (cephalosporin resistant). (A) The protein sequences from FA19, 35/02, and H041
were aligned by ClustalX (version 2.0.10 [37]). Dots represent identical amino acids, a dash represents a deletion, the active-site motifs (i.e., SxxK, SxN, and KTG)
are indicated by boxes, and the boundaries of the modules (see below) are depicted by arrows. (B) Schematic showing the modules in PBP2 used to identify the
regions of PBP2H041 containing amino acids that confer resistance to ceftriaxone and cefixime. The protein sequence (with numbers denoting the amino acid
positions of the junctions) is shown at the top, and the corresponding DNA with the silent restriction sites is shown at the bottom.
Resistance-Conferring Mutations in Gonococcal PBP2H041
July 2013 Volume 57 Number 7 aac.asm.org 3031
PBP2H041 that differ from those in PBP235/02 are responsible for
conferring the large increases in cephalosporin resistance. In a
previous study to define the important amino acids that increase
resistance in the mosaic penA35 allele (25), we generated con-
structs in wild-type penA and penA35 with silent restriction sites to
create six modules (called mod0 to mod5) that could be replaced
by corresponding modules in the other gene (Fig. 1B). This ap-
proach allowed us to identify regions of penA35 that contained the
most important amino acids for increasing resistance to ceftriax-
one and cefixime, and we used a similar strategy to identify the
regions containing crucial amino acids involved in resistance in
penA41.
Identification of the key amino acids in penA41 that confer
substantially increased resistance to expanded-spectrum ceph-
alosporins. Of the 12 mutations in the penicillin-binding domain
of PBP2, 4 are in mod1, 6 are in mod2, and 2 are in mod3 (we have
shown previously [25] that mutations in mod0 comprising the
first 300 amino acids have no effect on the MIC, and thus, we did
not examine the lone mutation in this region). We first focused on
mod1 and mod2 by transferring mod1, mod2, or mod1 and mod2
together from H041 into penA35, transforming the resulting con-
structs into FA19, and selecting for increased cefixime resistance.
Transfer of mod1 and of mod1 and mod2 together, but not mod2
alone, increased the MIC of cefixime. Mutations within mod2
were therefore discounted, and we focused on the mutations in
mod1. The 4 amino acid mutations residing in mod1 of PBP2H041
that differ from PBP235/02 are A311V, T316P, A328T, and S341P
(Fig. 1A). These mutations were introduced individually into
penA35, the constructs were transformed into FA19, and resistant
colonies were selected with cefixime concentrations just above the
MIC for FA19 penA35. Of these, only constructs with an A311V or
T316P mutation gave rise to colonies, with each mutation confer-
ring about the same increase in MICs of the expanded-spectrum
cephalosporins (Fig. 3). We also constructed a strain containing
PBP235/02 with an A311V/T316P double mutation, and the two
mutations were additive, with an MIC 2-fold higher than that
with either individual mutation alone. However, these two muta-
FIG 2 Increases in the MICs of ceftriaxone and cefixime in FA19 or FA6140
transformed with the penA alleles from either 35/02 (penA35) or H041
(penA41). (A) MICs of ceftriaxone and cefixime for the indicated penA alleles
transformed into FA19; (B) MICs of ceftriaxone and cefixime for the indicated
penA alleles transformed into FA6140. Values are the averages of a minimum
of 3 separate determinations (usually 3 to 6) and are indicated above the bar.
FIG 3 Increases in the MICs of ceftriaxone and cefixime conferred by penA35
containing mutations from penA41. The indicated mutations were incorpo-
rated into the penA35 allele, the resulting DNA constructs were used to trans-
form FA19 to increased cefixime resistance, and the penA sequences of indi-
vidual transformants were confirmed by PCR amplification and sequencing.
The MICs of the two expanded-spectrum cephalosporins were determined by
agar dilution on GCB plates containing 2-fold increases in the concentra-
tions of the two antibiotics for a minimum of 2 independent transformants
(usually 3 to 4).
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tions together conferred only 30% of the cephalosporin resistance
contributed by penA41, indicating that other mutations present in
penA41 are also important for increasing resistance (Fig. 3).
We next examined the last remaining mutations in penA41,
T483S and T485I, that are present in mod3. These mutations, both
individually and together, were introduced into both penA35 and
penA35 encoding both the A311V and V316P codon mutations
(penA35-A311V/V316P), the resulting plasmids were trans-
formed into FA19, and transformants with MICs of cefixime
above those containing the parental genes were selected. Colonies
were obtained with both the T483S single mutation and the
T483S/T485I double mutation but not with the T485I single
mutation, and initial experiments indicated that the MICs of the
transformants with just the T483S mutation were no different
than those with both mutations, so we focused solely on T483S.
Transformants carrying penA35-T483S had an 2-fold increase
in the MIC of ceftriaxone compared to either the penA35-A311V
or -V316P mutant alone and about the same MIC as both of these
mutations together, whereas the MIC of cefixime was about the
same as that for transformants containing the two individual
mod1 mutations (Fig. 3). However, when T483S was incorporated
into the penA35-A311V/V316P double mutant, the MICs of both
ceftriaxone and cefixime increased to essentially the same levels as
those for FA19 harboring penA41, i.e., nearly 15-fold higher than
those for FA19 harboring penA35.
To confirm that these three amino acid changes (A311V,
V316P, and T483S) were the key mutations in penA41, we reverted
the three residues in penA41 back to the amino acids found in
penA35 and transformed the construct into FA19. Transformants
of the reverted penA41 allele had MICs of both ceftriaxone and ce-
fixime that were identical to those for FA19 harboring penA35 (Fig.
3). These data clearly show that only three codon alterations, A311V,
V316P, and T483S, are responsible for the substantially increased
cephalosporin resistance of penA41 over penA35 (Fig. 3).
Acylation rates of PBP2 variants with penicillin G, ceftriax-
one, and cefixime. The second-order acylation rate constants for
key mutants (Table 1) were determined for penicillin G, ceftriax-
one, and cefixime, as described in Materials and Methods. PBP2
from H041 showed a remarkable 11,000-fold decrease in the
k2/Ks value for cefixime and a 2,300-fold decrease for ceftriaxone
compared to wild-type PBP2, highlighting the effectiveness of ac-
tive-site remodeling in lowering the acylation rates of the expand-
ed-spectrum cephalosporins without completely ablating essen-
tial transpeptidase activity. The k2/Ks values for the A311V and
T316P (double), T483S (single), and A311V, T316P, and T483S
(triple) PBP235/02 mutants generally followed a pattern consistent
with the cephalosporin MICs, although it is difficult to derive an
exact relationship between the MICs and acylation rates.
We also purified wild-type PBP2 harboring the three muta-
tions and determined the k2/Ks for penicillin G, ceftriaxone, and
cefixime. In the wild-type background, these mutations had a
minimal effect (less than a 2-fold decrease) on the acylation rate
constants of all three antibiotics relative to wild-type PBP2, but in
the PBP235/02 background, they decreased the acylation rate con-
stants by 6- to 35-fold compared to PBP235/02 (Table 1). Thus, the
capacity of the three mutations to markedly alter the acylation
rates of the antibiotics is dependent on other mutations present in
mosaic PBP2 variants. These results are consistent with our pre-
vious study demonstrating the complex interdependency of mu-
tations in the mosaic PBP2 background required to alter the acy-
lation rate constants of -lactam antibiotics (25).
DISCUSSION
The emergence of H041, which is essentially untreatable with ex-
panded-spectrum cephalosporins and most other antimicrobials,
is a wake-up call that the postantibiotic era for treatment of N.
gonorrhoeae infections may be imminent (3, 24). The spread of
this high-level ceftriaxone-resistant strain or other ceftriaxone-
resistant strains such as those recently identified in France (29)
and Spain (34) would be a public health disaster. Part of the re-
sponse to this threat is to identify the amino acids that result in
cephalosporin resistance in order to carry out more effective sur-
veillance of the spread of cephalosporin-resistant strains, to un-
derstand the mechanisms underlying this resistance, and to de-
velop genetic testing methods for cephalosporin resistance in the
future.
In this study, we have identified three amino acid alterations in
PBP2 from H041, A311V, V316P, and T483S, that together are
responsible for conferring high-level resistance to expanded-spec-
trum cephalosporins above that conferred by mosaic penA alleles
from strains such as 35/02 (16, 22, 25). These mutations, when
incorporated into the mosaic penA35 allele, increase the MICs of
ceftriaxone and cefixime for a wild-type recipient strain by 15-fold
(to essentially the same level as the penA41 allele itself) over the
same strain harboring the traditional penA35 mosaic XXIX allele
(Fig. 3). The capacity of these mutations to decrease the acylation
rates of the expanded-spectrum cephalosporins for PBP2 (and
thereby increase the MICs), however, depends on the presence of
TABLE 1 Acylation rate constants for PBP2 variantsb
Protein
Mean acylation rate constant (M1 s1) 	 SD
Ceftriaxone Cefixime Penicillin G
PBP2WTa 1,710,000 	 90,000 1,480,000 	 22,000 75,700 	 2,300
PBP235/02a 11,300 	 400 7,170 	 300 510 	 90
PBP2H041 741 	 28 135 	 21 55 	 14
PBP235/02-A311V/V316P 19,900 	 1,200 2,480 	 210 890 	 40
PBP235/02-T483S 1,730 	 120 710 	 32 62 	 8
PBP235/02-A311V/V316P/T483S 1,230 	 28 193 	 10 88 	 8
PBP2WT-A311V/V316P/T483S 1,300,000 	 110,000 660,000 	 41,000 43,000 	 2,000
a Values were reported previously by Tomberg et al. (25).
b The acylation rate constants were derived from kinetic measurements of the formation of the acyl-enzyme complex, as described in Materials and Methods. The rates were
determined directly with [14C]penicillin G and by the competition method with ceftriaxone and cefixime. Values were derived from a minimum of 3 (usually 3 to 7) separate
determinations. PBP2WT, PBP2 from strain FA19; PBP235/02, PBP2 from strain 35/02; PBP2H041, PBP2 from strain H041.
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other mutations in the mosaic PBP2 background, as the three
mutations have very little effect when incorporated into wild-type
PBP2 (Table 1). These data highlight the ability of a small number
of mutations to confer very large increases in resistance when
incorporated into a mosaic penA allele and also reflect the com-
plex interactions between the mutations within a given PBP2
background.
One of the major hurdles inherent in the evolution of cepha-
losporin-resistant penA alleles is to remodel the active site of PBP2
to cause a decrease in acylation rates with -lactam antibiotics
while retaining essential transpeptidase (TPase) activity. Because
-lactam antibiotics are substrate analogs, these changes must be
subtle and, by extension, must affect the reaction steps that are
most important for rapid acylation by -lactams but less impor-
tant for transpeptidation. Unfortunately, it is not possible to
quantify TPase activity of this class (class B) of PBPs in vitro, and
the only assessment of transpeptidase activity is a qualitative de-
termination of whether the encoded PBP2 variant supports
growth of gonococci. Moreover, since mutations that lower acy-
lation with -lactam antibiotics may also lower TPase activity of
PBP2, it is unknown how much TPase activity can be lost while
still allowing normal growth. We know only that such mutations
do not cripple TPase function and that whatever activity is re-
tained is sufficient for growth of H041.
It is also worth noting that although we have focused primarily
on resistance to ceftriaxone and cefixime, our acylation data indi-
cate that mutations present in PBP2 from H041 markedly de-
crease the k2/Ks values for penicillin G as well as for the two ceph-
alosporins (Table 1). This indicates that the mutations are not
simply discriminating against the different structures of the ceph-
alosporins relative to penicillin but are probably affecting acyla-
tion in general. Hence, even as clinical strains drive toward ceph-
alosporin resistance, it is unlikely that penicillin will ever again
become effective against gonorrhea, as the mutations introduced
into the mosaic alleles that decrease acylation by cephalosporins
also decrease acylation by penicillins.
Now that the mutations in penA41 that confer the large in-
crease in cephalosporin resistance to recipient strains above and
beyond that already conferred by the mosaic penA35 allele have
been identified, it is important to define how these three amino
acid changes alter the structure of PBP2. In lieu of a crystal struc-
ture of PBP2H041, we can examine the positions of these amino
acid alterations in the crystal structure of wild-type PBP2 (31) to
infer how these mutations might affect acylation by -lactam an-
tibiotics. The locations of the three mutations in the wild-type
structure are shown in Fig. 4. Two of these mutations (A311V and
V316P) are present on the 
2 helix either within or just down-
stream of the SxxK active-site motif containing the Ser nucleo-
phile (Ser310) that attacks the -lactam–D-Ala-D-Ala bond,
whereas the T483S mutation is on a loop connecting 
10 with 3
(the latter of which contains the KTG active-site motif). These
mutations are discussed in turn below.
A311V/V316P. The A311V and V316P mutations on 
2 are in
the same location as two of the three mutations that we previously
investigated in mosaic penA alleles (25). The data from that study
showed that I312M and V316T were important for the interme-
diate-level cephalosporin resistance phenotype conferred by the
penA35 allele, as reversion of these two mutations to the wild type
reduced the MICs of ceftriaxone and cefixime by 4-fold. Along
with the I312M mutation, PBP2 from H041 contains a new mu-
tation at Ala311 (A311V) and a different mutation at Val316,
V316P (Fig. 4).
As shown in Fig. 4, Ala311 and Val316 are present on the same

2 helix that contains the serine nucleophile Ser310, with Ala311
being immediately adjacent. Changes in the hydrophobic packing
of 
2 conferred by the mutations could change the dynamics of
transition state formation and lead to decreases in k2/Ks, the acy-
lation rate constant. Moreover, the differences between the amino
acids at residue 316 between penA35 and penA41, with the latter
having a proline instead of threonine, could have a significant
impact on the structure of 
2. Prolines are known to promote
helix kinking, and so it will be of particular interest to determine
the structure of PBP2 from H041 to see if this mutation has any
impact on the helical structure of 
2.
T483S. The T483S mutation is unique to H041 penA and in a
region that is not highly divergent in mosaic alleles. While the
T483S mutation is very conservative, the loss of the methyl group
of Thr has a large impact on acylation (Fig. 3 and Table 1). Thr483
is on a loop preceding the 3 strand containing the KTG motif and
is situated near the active site. Modeling of the cephalosporin ce-
furoxime into the active site of PBP2 (no acylated structure of
PBP2 is available) reveals that the hydroxyl group of Thr483 is
very close to the carboxyl group of cefuroxime (Fig. 4). Alteration
of this interaction may increase the activation energy for transi-
tion state formation and thus lead to decreases in the acylation rate
(k2), or alternatively, Thr483 may be important in binding (Ks),
and its mutation to Ser increases Ks and thus lowers the second-
order acylation rate (k2/Ks).
In conclusion, the first strain (H041) with high-level resistance to
ceftriaxone (MIC  2 to 4 g/ml) and resistance to most other anti-
microbials was isolated recently in Japan (24). We have identified the
3 amino acid mutations in penA41 that confer essentially all of the
increased resistance to expanded-spectrum cephalosporins over that
















FIG 4 Structure of PBP2 with modeled cefuroxime showing the locations of the
three mutations from PBP2H041 that confer essentially all of the increased resis-
tance above that of PBP235/02. The A311V and V316P mutations are located on the
opposite side of the 
2 helix containing the active-site nucleophile Ser310. These
mutations may perturb the position of Ser310, thus increasing the activation en-
ergy of the transition state during acylation and lowering the acylation rate. The
T483S mutation is on a loop preceding the 3 strand containing the KTG motif
(pictured) and is ideally located to interact with the carboxylate from cefuroxime.
Cefuroxime was modeled into the active site based on superimposition of PBP2
with PBP2X from Streptococcus pneumoniae (38).
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these amino acid alterations (A311V and V316P) are in a region of
PBP2 already known to harbor resistance-changing mutations, but
the third (T483S) is in a novel location, where it may interact with the
carboxylate moiety of -lactam antibiotics. The effect of these muta-
tions on peptidoglycan synthesis, in vitro growth, and biological fit-
ness in vivo remain important questions to address in order to assess
the propensity of strains harboring this allele to cause disease out-
breaks. In addition to the large decrease in the acylation rate,
PBP2H041 may also have a marked reduction in transpeptidase activ-
ity, thereby causing a decrease in fitness. However, H041 and similar
strains might also contain compensatory mutations that mitigate the
fitness cost, which are frequently obtained in the laboratory (35, 36)
and are likely occur in nature as well. Studies to address these ques-
tions are currently in progress.
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